Patients with vision decline as indication for BBT, N = 6 |
Patients
with vision decline as indication for BBT, N = 6 |
Patients with vision
decline as indication for BBT, N = 6 |
Patients with vision decline as
indication for BBT, N = 6 |
Patients with vision decline as indication
for BBT, N = 6 |
Patients with vision decline as indication for BBT, N =
6 |
Patients with vision decline as indication for BBT, N = 6 |
Patients
with vision decline as indication for BBT, N = 6 |
Patients with vision
decline as indication for BBT, N = 6 |
Patients with vision decline as
indication for BBT, N = 6 |
Patients with vision decline as indication
for BBT, N = 6 |
Patients with vision decline as indication for BBT, N =
6 |
Patients with radiographic progression alone as indication for BBT, N =
11 |
Patients with radiographic progression alone as indication for BBT,
N = 11 |
Patients with radiographic progression alone as indication for
BBT, N = 11 |
Patients with radiographic progression alone as indication
for BBT, N = 11 |
Patients with radiographic progression alone as
indication for BBT, N = 11 |
Patients with radiographic progression
alone as indication for BBT, N = 11 |
Patients with radiographic
progression alone as indication for BBT, N = 11 |
Patients with
radiographic progression alone as indication for BBT, N = 11 |
Patients
with radiographic progression alone as indication for BBT, N = 11 |
Patients with radiographic progression alone as indication for BBT, N =
11 |
Patients with radiographic progression alone as indication for BBT,
N = 11 |
Patients with radiographic progression alone as indication for
BBT, N = 11 |
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|
*Follow-up time from treatment start to last vision assessment; †Visual
acuity (VA) and visual field (VF) assessments at last follow-up or at
progression
Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic
astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based
therapy; R, radiographic progression; V, vision decline; BEV,
bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data
|